Biologics in juvenile idiopathic arthritis: a narrative review.

about

Non-pharmacological options for managing chronic musculoskeletal pain in children with pediatric rheumatic disease: a systematic review T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis

P2860

Q57167873-6154E811-BDC6-4363-8004-6BEDC0EECE11 Q58799147-84043618-99D5-4150-B57D-E461F4ECEAD7

P2860

Biologics in juvenile idiopathic arthritis: a narrative review.

Item

http://www.wikidata.org/entity/Q39446782

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Biologics in juvenile idiopathic arthritis: a narrative review.

@en

Biologics in juvenile idiopathic arthritis: a narrative review.

@nl

type

Item

label

Biologics in juvenile idiopathic arthritis: a narrative review.

@en

Biologics in juvenile idiopathic arthritis: a narrative review.

@nl

prefLabel

Biologics in juvenile idiopathic arthritis: a narrative review.

@en

Biologics in juvenile idiopathic arthritis: a narrative review.

@nl

P1476

Biologics in juvenile idiopathic arthritis: a narrative review.

@en

P2093

Clara Malattia

http://www.w3.org/2001/XMLSchema#string

Federica Vanoni

http://www.w3.org/2001/XMLSchema#string

P2860

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

P2888

s00431-017-2960-6

P304

1147-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00431-017-2960-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

F Minoia

P577

2017-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28725955

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

Biologics in juvenile idiopathic arthritis: a narrative review.

about

P2860

P2860

Biologics in juvenile idiopathic arthritis: a narrative review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921